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‘Non mors timenda, sed vita non incohata!’ 
“It is not death that one should fear, but one should fear never beginning to live!” 
Probably not Marcus Aurelius. 
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ABSTRACT 
 
 
 
Autophagy is a fundamental catabolic process, which is utilized by nearly every cell and 
tissue type upon stress exposure and has been shown to contribute to resistance to 
chemotherapy in a variety of cancers. The subject of this thesis is to shed light on the role of 
autophagy in chemotherapy and to investigate novel regulators of autophagy.  
 
 
Multiple clinical trials have been started in order to overcome resistance to standard therapy 
by combining it with lysosomal inhibitor hydroxychloroquine, yet with limited success. This 
drug has been shown to have poor cell uptake properties in solid tumors due to tumor acidosis. 
In paper I we found that the compound Salinomycin is a potent autophagy inhibitor in 
multiple cancer cell lines, especially under acidic conditions. Salinomycin was able to 
penetrate the acidic core of multicellular spheroids and decrease cell viability and clonogenic 
survival of colorectal cancer cells. We also show that Salinomycin efficiently blocked 
autophagic flux in breast cancer cells. In particular, cancer stem cells derived from cell lines 
or primary breast cancer tumors showed reduced viability and reduced capability to form 
mammospheres under Salinomycin treatment. Using mass spectrometry, we could confirm 
pH-dependent intracellular accumulation of Salinomycin. This data proves the potency of 
Salinomycin as an anti-cancer drug with capacities to modulate autophagy in the acidic tumor 
microenvironment. 
 
 
Part of the standard treatment regimen of pediatric patients with Acute Lymphoblastic 
Leukemia (ALL) are glucocorticoids (GC). This metabolic hormone is effective in inducing 
cell death in ALL cells. GC mediated inhibition of glucose uptake and upregulation of 
catabolic processes such as autophagy have previously been reported. In paper II we 
addressed in detail what metabolic changes occur upon GC treatment in ALL cell lines by 
parallel time-course proteomics, metabolomics and isotope tracing, and by confirming 
selected findings by cross-referencing with publicly available microarray data and 
experimentally by qRT-PCR. Our findings confirmed the onset of growth arrest, autophagy 
and apoptosis. Not only glucose but also glutamine entry into the Citric-Acid-Cycle was 
inhibited contrasting the upregulation of glutamine-ammonia-ligase (GLUL) expression 
suggesting the induction of glutamine synthesis. Potentiating the GLUL-mediated reaction 
rescued cell viability and reduced autophagic flux suggesting that GLUL induction and 
glutamine synthesis are relevant for the autophagy induction and sensitivity of ALL cells to 
GCs. This data provides a comprehensive overview of metabolic changes in ALL cells upon 
GCs' treatment and may shed light on the mechanism of GC-induced cell death in ALL cells. 
  
   
 
 
 
 
 
 
 
In paper III we used high-content microscopy to screen the FIMM drug library consisting 
of 306 anticancer drugs and identified 104 autophagy modulators, of which 16 showed cell 
death potentiation upon siRNA mediated knock-down of ATG7 (autophagy-related protein 
7) and VPS34 (vacuolar protein sorting 34), key regulators of autophagy. We validated the 
hits in 2 breast cancer cell lines, MDA-MB231 and MCF7, and continued to characterize two 
of the hits, Erlotinib and Sunitinib, in detail. The collaboration with Sprint Bioscience led to 
the development of SB02024, a specific inhibitor of the VPS34 kinase. We showed that 
SB02024 could block autophagy in vitro and in in vivo xenograft mouse models. 
Combination of SB02024 with Sunitinib and Erlotinib increased cytotoxicity by these drugs 
in either 2D cell culture, colony formation assays, or, in case of Sunitinib, in cells grown in 
3D as multicellular spheroids. This data further strengthens the notion that using VPS34 
inhibitors in combination with targeted tyrosine kinase inhibitor-based therapy, and 
particularly Sunitinib, can overcome resistance and emphasizes their value in cancer 
treatment. 
 
 
RAS protein activator like 2 (RASAL2) is a known tumor-suppressor regulating members of 
the RAS-family of oncoproteins. In paper IV we describe for the first time a role for 
RASAL2 in the induction of autophagy. We found that autophagy induction via 
pharmaceutical mTOR inhibition or amino acid-starvation increased RASAL2 transcription. 
Furthermore, RASAL2 protein levels were regulated by autophagy-dependent protein 
degradation. Thus, in the starved cells, RASAL2 mRNA levels were induced while protein 
levels declined. Also, depletion of autophagy-related protein 7 (ATG7) that impaired 
autophagy process resulted in a striking increase in RASAL2 protein levels. RNAi-mediated 
knockdown of RASAL2 inhibited LC3-II accumulation or GFP-LC3 puncta formation. In 
silico analysis of RASAL2 revealed two potential LC3 interacting region motifs (LIR), which 
could point to an interaction between these two proteins. These data suggest that RASAL2 is 
involved in autophagy and is regulated by autophagy in a negative feedback manner.  
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 2 
PREAMBLE 
One stands in awe of the complexity of life: billions of years of evolution have shaped archaea 
as well as pro- and eukaryotes in their ability to survive in the most diverse habitats. Life has 
evolved to thrive in hostile environments, from icy landscapes in the Arctic to scorching 
volcanic sulphur vents deep in the ocean, continually adapting to the conditions of the 
surroundings. Large intertwined networks carefully shaped by evolution to maintain 
homeostasis make this adaption possible while being flexible enough to change if necessary. 
The central dogma of molecular biology is at its heart, describing the residue-by-residue 
transfer of sequential information from DNA to RNA to protein. Researchers have identified 
transcriptional/translational regulation and modifications, positive and negative feedback 
loops, epigenetics, non-coding RNA and many other mechanisms, which enable the cells to 
react on internal and external stimuli, whilst keeping a delicate balance. However, what 
happens when this equilibrium is being tipped over? 
We have extended our life expectancy by a great deal due to science and technology by limiting 
our exposure to life-threatening conditions such as malnutrition and pathogens. We have 
tremendously progressed in our understanding of diseases in general; but the longer we live, 
the more can get wrong in such a complex network. Cancer, a term used to classify a vast 
number of genetic and epigenetic diseases, is a consequence of deregulation of these networks, 
and the second leading cause of the death worldwide. According to prospective studies of the 
World Health Organization, one in three will develop cancer in their lifetime, while one in five 
will die from it (Stewart & Wild 2014).  
1 CANCER 
What is cancer? As beforementioned it is a blanket term for a multitude of diseases featuring 
uncontrolled cell growth. Cancer is practically a given outcome in every multicellular organism 
since every somatic cell shares the same genetic information and thus the potential to proliferate 
(Martincorena & Campbell 2015). A paradigm in cancer research established in the past 100 
years is the somatic mutation theory of carcinogenesis, describing sporadic cancers (95% of all 
cancers) (Soto & Sonnenschein 2004). The quintessence of this theory states that mutations 
acquired over time in a single somatic cell give rise to a tumor, which implies, at least in the 
early stages of tumor progression, monoclonality. While studying these mutations two 
important concepts were developed: 1. Oncogenes were identified through gain-of-function 
studies, where mutation in the gene drive transformation into cancer (Stewart & Wild 2014). 
2. Tumor-Suppressor genes were identified through the studies of hereditary cancer, where 
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mutations inactivate the gene function contributing to the transformation into cancer (Stewart 
& Wild 2014). The influential landmark review “The hallmarks of cancer” by Hanahan & 
Weinberg in 2000 sought to simplify and identify the essential, through mutations acquired 
capabilities, which unifies all cancerous diseases. The six hallmarks were ‘self-sufficiency in 
growth signals,’ ‘insensitivity to anti-growth signals,’ ‘evading apoptosis,’ ‘sustained 
angiogenesis,’ ‘limitless replicative potential’ and ‘tissue invasion and metastasis’; notably 
only the last hallmark distinguishes, in general, benign from malignant growths. Cancer 
research accelerated in the following decade; improvements in sequencing techniques led to a 
revolution in cancer genomics. As a consequence, researchers were able to discriminate 
mutations further, labelling those, which cause a proliferative advantage and promote cancer 
development as “driver mutations,” in contrast to “passenger mutations,” which do not promote 
tumorigenesis (Bozic et al. 2010). The further research progressed the clearer it became that 
the view on cancer as a homogenous mass of proliferating cells was an oversimplification. The 
follow up review of Hanahan & Weinberg: “Hallmarks of cancer: the next generation” in 2011 
extended, to a degree, the necessary properties of malignant transformation, by emphasizing 
the significance of the interaction between the tumor and normal cells, namely the role of the 
immune system, inflammation and altered tumor cell metabolism, especially in the tumor 
microenvironment (Hanahan & Weinberg 2011). Figure 1 schematically describes major 
characteristics that cells acquire and modifications they are subjected to for cancer to develop 
and progress. Nevertheless, with new whole-genome and whole-transcriptome sequencing 
techniques on the single-cell level and sufficient coverage to identify point mutations, the field 
has started to decompose tumor populations, analyze rare cell populations associated with 
tumor progression and study cancer evolution through lineage tracing (Baslan & Hicks 2017). 
1.1 CANCER STEM CELLS & TUMOR HETEROGENEITY   
This deconvolution of tumors resulted in the identification of Cancer-stem cells (CSC), a 
subpopulation of cells with tumor-initiating ability, which are believed to contribute to 
chemotherapy resistance, metastasis and disease relapse (Batlle & Clevers 2017). Insights of 
hematopoiesis were paving the way for the establishment of a CSC model, which in a way 
reflects hematopoietic stem cell development. Here are the major assumptions of this 
hypothesis: 1. The tumor heterogeneity is largely a consequence of the hierarchical tissue 
organization, which is often a reflection of the tissue of origin. 2. Self-renewing CSC, which 
typically account only for a small fraction of the tumor, provide the supply of cells; the bulk of 
the tumor consists of non-CSC cells, which have only limited proliferative capacity. 3. CSC 
identity is fixed; there is only limited plasticity. 4. CSC are therapy resistant and thus are a 
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major cause of relapse (Kreso & Dick 2014). Lately, this model was revised, since extensive 
lineage tracing experiments have shown evidence for a greater plasticity. This hints towards 
the existence of a CSC niche, in which CSC compete for niche space and also some of the 
differentiated cells can undergo dedifferentiation when exposed to the niche signals (Plaks et 
al. 2015; Batlle & Clevers 2017). Understandably, CSCs have become highly relevant targets 
in cancer research. It was proposed that high autophagic flux is one of the key traits of CSCs 
helping them to withstand harsh conditions of hypoxia and nutrient deprivation (Marcucci et 
al. 2017). Autophagy modulation could thus sensitize CSC to anticancer therapy. The other 
resistance mechanisms in CSC include, but are not limited to, an increased drug-efflux through 
membrane transport, a heightened capacity to withstand oxidative stress through aldehyde 
dehydrogenase activity and an enhanced DNA damage response (Cojoc et al. 2015). 
 
Figure 1: Major characteristics that cell acquire and modifications they are subjected to for cancer to develop and to 
progress.8  
1.2 BREAST CANCER 
Breast cancer is the second most common cancer worldwide and the leading cause of cancer 
mortality in women. Initially oncologists attempted to distinguish breast cancer subtypes solely 
on histopathology, which resulted in 70-80% of all breast cancer cases falling only into one of 
three categories, namely invasive lobular carcinoma, invasive ductal carcinoma or ‘not 
otherwise specified’ (Viale 2012). Subsequently, a biological classification for early breast 
cancer was established to predict the response to anticancer therapy in multiple consensus 
conferences in St. Gallen. Immunohistological staining of the proliferation marker Ki-67, and 
expression levels of estrogen- and progesterone-receptor proved to be valuable tools in 
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deciphering breast cancer subtypes (Gnant et al. 2011). Extensive genomic and bioinformatic 
analysis redefined the classification based on gene expression, resulting in an intrinsic 
molecular classification established through microarray profiling (Sorlie et al. 2003). This 
organization led to a better understanding of breast cancer biology, a better stratification of 
patient groups resulting in heightened therapeutic success and longer patient survival (Prat et 
al. 2015). The molecular subtypes are ER-positive (luminal), human epidermal growth factor 
receptor 2 (HER2)-enriched, basal-like and normal-like. The luminal subtypes are further 
distinguished in luminal A and luminal B, which differ especially regarding proliferation, with 
the latter being more proliferative, and also less sensitive to hormone-based treatment and more 
sensitive to chemotherapy than luminal A tumors (Ignatiadis & Sotiriou 2013).  
Even within these sub-types, a varying degree of heterogeneity has been observed at both 
molecular, genomic and phenotypic level (Karthik et al. 2017) . Although this heterogeneity 
may not at the moment have a large impact on the molecular diagnostics, it will provide an 
important guidance for the formulation of personalized anti-cancer treatment and for the 
optimal use of targeted therapy (see below).  
1.3 ACUTE LYMPHOBLASTIC LEUKEMIA 
Acute lymphoblastic leukemia, ALL, is the most common malignancy in children manifested 
by an expansion of immature B or T cells (Inaba et al. 2013). ALL is a heterogeneous disease 
with more than eleven genetic sub-groups that have been described for only pre-B-ALL 
(Downing et al. 2012). Advances in diagnostic tools, such as detection of recurring genetic 
abnormalities and multi-factorial FACS analysis lead to a successful combination of risk-based 
stratification and multi-agent chemotherapy, which has significantly increased survival of the 
patients in recent years. The current stratification of ALL is based on genetic abnormalities 
(Pui et al. 2015). Interestingly, however, they are insufficient to fully explain ALL 
pathogenesis as they, on their own, fail to induce leukemia in in vivo models (Inaba et al. 2013). 
This inconsistency may indicate that additional yet uncovered factors are involved in the ALL 
pathology. Despite the advances in the treatment, 10-15% of patients will still relapse. ALL 
relapse has been linked to the persistence of stem-like progenitor cells (Mullighan et al. 2008), 
which are less proliferating and are not readily eliminated by the treatment. These cells, first 
discovered in acute myeloid leukemia, AML, may represent the subset of cells that have been 
shown to be able to engraft in mice in patient-derived ALL xenograft (PDX) models (Meyer 
et al. 2011). The relapsed disease becomes highly resistant to therapy, and a high proportion 
of patients with relapse will die of the disease.  
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Despite carefully monitored chromosomal translocations and other genetic changes in ALL, 
treatment protocols of pediatric ALL in Sweden do not include any targeted therapy based on 
these genetic, but rather cytotoxic drugs that are directed against particular biological features 
of these leukemic cells. These features include the inability to produce L-asparagine (resulting 
in high sensitivity to the enzyme L-asparaginase) and the high sensitivity to metabolic 
hormones glucocorticoids (GC) dexamethasone or prednisolone (Pui et al. 2015). It is still 
unknown what are the mechanisms underlying the high sensitivity of leukemic cells to GCs. 
Pre-B-ALL cells were shown to rely rather on glycolysis for energy production instead of 
oxidative phosphorylation (OXPHOS), and they express high levels of glucose transporters on 
their surface (Boag et al. 2006). The switch to glucose metabolism for energy production may 
depend on the commonly occurring mutations in transcription factors PAX5 and IKZF1, which 
otherwise act as metabolic gatekeepers in this stage of B-cell differentiation (Chan et al. 2017). 
As GCs regulate glucose uptake and metabolism in different tissues, this may underlie their 
pronounced cytotoxic effects on ALL cells that highly depend on glucose metabolism. Thus, 
perhaps not surprisingly, GC resistance in primary ALL cells was associated with an increased 
expression of glucose metabolism genes and enhanced glycolysis (Hulleman et al. 2009; 
Holleman et al. 2009). However, the mechanisms of GC-induced cell death in ALL remains 
not fully understood.  
1.4 CANCER THERAPY 
Anti-cancer therapy was dominated by surgery and radiotherapy up until the 1960s. These 
methods were effective on a short-term, but remission rates plateaued at around 30% (DeVita 
& Chu 2008). Due to military mustard gas experiments in the middle of the 20th century 
(Connor 2018) and the subsequently depletion of lymph nodes and bone marrow observed in 
treated subjects, one of the first chemotherapeutics was discovered: nitrogen mustard 
derivatives that target bone marrow and leukocytes and were since successfully used in therapy 
of lymphomas (DeVita & Chu 2008). The development of animal models, especially the 
establishment of a transplantable tumor system in rodents led to the possibility to test novel 
compounds for anticancer properties (Grever et al. 1992). Thus initially, newly discovered 
drugs were cytotoxic to fast proliferating cells in general, hence as a side effect also 
immunosuppressive. Most of the discovered compounds were used against hematological 
malignancies, but the observation that rat hepatoma cells have an increased uptake of Uracil 
led to the first drug, which is up until today part of some treatment protocols against solid 
tumors: 5-fluorouracil (HEIDELBERGER et al. 1957). 
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Although governed by common mechanisms, each cancer disease is characterized by features 
specific to each individual tumor and therefore individual treatment regimen needs to be 
composed for each patient. This approach, called personalized cancer medicine, is being 
applied worldwide including Karolinska hospital (Jackson & Chester 2014). Specific 
mutations in such genes as tyrosine kinases led to a discovery of tyrosine kinase inhibitors that 
have revolutionized anti-cancer treatment. Inhibitors against BCR-ABL, EGFR, VEGFR, 
HER2, some of them used in this thesis, and many others have been developed (Neal & Sledge 
2014). At the same time, novel therapeutic targets for cancer treatment need to be explored to 
match tumor variations and heterogeneity in cancer management. Moreover, cancer cells are 
highly adaptable, developing mutations or activating survival pathways in response to 
treatments (Fisher et al. 2013). One of such pathways is autophagy, the subject of this thesis. 
The development of novel therapies targeting autophagy is subject of one of the papers in this 
thesis, as well as an attempt to overcome drug resistance to tyrosine kinase inhibitors using 
autophagy inhibitors. 
2 AUTOPHAGY 
Autophagy is an evolutionary conserved catabolic process, in which cell own constitutes 
(damaged organelles, protein aggregates) are recycled by delivering them to lysosomes. This 
‘self-cannibalization’ was first reported in mammalian cells more than five decades ago 
(Novikoff & Essner 1962). This fundamental process is observed in nearly every eukaryotic 
cell (Reggiori & Klionsky 2002), but it is highly tissue and context specific; hence basal levels 
of autophagy and the dependence on the cell origin in this process vary between different 
tissues (Mizushima & Komatsu 2011). 
A critical function of autophagy in cellular homeostasis is protein and organelle quality control 
(Mizushima et al. 2008), but it nevertheless took many years to recognize its beneficial role in 
the cell as a recycling mechanism. The observation that dying cells often increase 
autophagosome generation led to a premature stigma: the association with cell death, which 
led to the description of autophagy as a Type II Programmed Cell death. Although parts of the 
autophagy machinery have been reported to be directly involved in apoptotic cell death 
(Denton et al. 2012; Grandér et al. 2009), the cytoprotective functions of autophagy under 
different stress stimuli, i.e. starvation, metabolic stress, Reactive Oxygen Species (ROS) 
generation or proteotoxicity, is undisputed (Mizushima & Komatsu 2011). 
Until 1990’s little was known about the autophagy pathway, and research was limited to 
phenotypical studies only. It was the work of the Ohsumi Lab, which paved the way in 
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understanding the proteins involved in autophagy, earning Yoshinori Ohsumi the Nobel prize 
in 2016. Having established a simple, yet elegant model system in yeast cells enabled him to 
identify many AuTophaGy-related genes (ATG) (Mizushima 2018).  
Autophagy has a significant impact on metabolism and protein degradation, which can 
influence half of the proteome of a cell (Mathew et al. 2014). Unsurprisingly, many human 
pathologies are associated with abnormalities in autophagy (Figure 2). Autophagy is being 
divided into three major types: Macro-, Micro- and Chaperone-mediated- autophagy. Both 
Micro- and Chaperone-mediated autophagy utilize a direct translocation of cargo into the 
lysosome. The former, by direct engulfment of the cytoplasm, the latter utilizes chaperons, 
which recognize target proteins (Mizushima et al. 2011). This doctoral thesis solely focuses 
on macroautophagy. 
 
Figure 2: Role of Autophagy in different tissues (Mizushima et al. 2008) 
Three steps characterize autophagy: 
• Initiation & Nucleation. The formation of a double-membrane vesicle called 
isolation-membrane or phagophore.  
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• Elongation & Closure. The elongation of the double membrane around specific cargo 
or cytosol. Characterized by Microtubule-associated protein 1A/1B-light chain 3 (LC3) 
lipidation and its incorporation into the autophagosome membrane.  
• Maturation and degradation. Fusion with endosomes and ultimately lysosomes, 
which provide the catalytic enzymes for the breakdown of the cargo.  
Next, to this division, there are two observed modi operandi: Selective and nonselective 
autophagy. Non-selectiveness in this context means the formation of the autophagosome 
unspecifically so that the content of the autophagosome is virtually indistinguishable from 
the surrounding cytoplasm. In this case, bulk protein degradation helps to supply the cells 
with free building blocks to overcome stressful periods such as starvation. Selective 
autophagy, on the other hand, describes the targeted degradation of proteins or cell organelles 
using autophagy adapters such as ubiquitin-binding protein p62/Sequestosome-1 
(p62/SQSTM1; subsequently called p62) and Neighbor of Brca1 gene (NBR1). The highly 
specialized autophagosomes are selectively sequestering cargo; the content is concentrated, 
and the cytoplasm is to a high degree absent. The autophagic adapters such as p62 determine 
the specificity of this process by bridging the gap between the to-be-degraded substrate and 
the core autophagy proteins via interaction with autophagy receptors such as LC3. The 
nomenclature of the different types of selective autophagy reflects the recognition and 
degradation of the particular cargo, i.e., Lipophagy for degradation of lipid droplets; 
Mitophagy for degradation of Mitochondria; Xenophagy for degradation of microbes and 
viruses (Rogov et al. 2014). Selective autophagy plays a critical role in the quality control of 
proteins and cell organelles. It is, for example, the sole mean of degradation of dysfunctional 
mitochondria, a source of DNA-damaging ROS and pro-apoptotic proteins (Rogov et al. 
2014).  
2.1 REGULATION OF AUTOPHAGY 
More than 30 proteins have been identified, which play a direct role in canonical autophagy, 
not mentioning here any of the lysosomal proteins. However, instances of non- canonical 
autophagy have been reported, which can occur independently of some critical components of 
the core-machinery (Codogno et al. 2012). 
2.1.1 Initiation – ULK1 and Beclin1-VPS34 
Two multi-protein complexes are essential in the initiation of canonical autophagy. The first 
complex is the Unc- 51 Like Autophagy Activating Kinase 1 (ULK1) complex, which is 
negatively regulated by the mechanistic Target Of Rapamycin (mTOR), a central pathway 
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modulating protein synthesis, cell growth and cell cycle progression (Figure 3). If nutrients or 
growth factors are present, mTOR phosphorylates ULK1 rendering the autophagy initiation 
complex inactive. Under starvation conditions this inhibitory signal is absent, and the ULK1 
complex can phosphorylate Beclin-1 enabling the formation of the second multi-protein 
complex, essential for the initiation of canonical autophagy. Beclin-1 has a Bcl-2 homology 3 
(BH3) domain, which gives it an ability to interact with members of the B-cell lymphoma 2 
(BCL2) family of proteins like BCL2, which is an anti-apoptotic protein and an autophagy 
inhibitor. Thus, under non-starved conditions, Beclin-1 is bound to BCL2 and is not able to 
recruit any proteins for complex formation and autophagy initiation. The phosphorylation by 
ULK1 disturbs this connection, and Beclin-1 can recruit Vacuolar protein sorting 34 (VPS34 ) 
and other proteins such as VPS15, Activating molecule in BECN1-regulated autophagy protein 
1 (Ambra1), and ATG14L as shown in Figure 4. 
 
Figure 3: Cell signaling regulating Autophagy. Blue color: Autophagy promoting factor; Red color: Autophagy inhibiting 
factor. (Brown et al. 1994) 
VPS34 is a Class-III PI3Kinase, which phosphorylates phosphatidylinositols producing 
phosphatidylinositol 3-phosphate [PI(3)P], a phospholipid essential for phagophore formation 
(Jaber et al. 2012). Members of the WD-repeat protein interacting with phosphoinositides 
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(WIPI) can subsequently bind the PI(3)P in the phagophore membrane and work as effectors 
in elongation and maturation of the autophagosome (Proikas-Cezanne et al. 2015).  
Depending on the cofactors bound to the Beclin-1-VPS34 complex, its function can be 
modulated. Thus, the presence of Ambra1 and ATG14L play an essential role in the initiation 
of the phagophore. On the other hand, when instead of these co-factors UVRAG is present in 
the complex, a role of the complex in autophagosome maturation has been observed 
(Funderburk et al. 2010). A third complex, called CII (as opposed to CI involved in autophagy) 
has been described, involved in endosomal maturation and trafficking (Levine et al. 2015). 
Figure 4: Canonical Autophagy Core Machinery (Dupont & Codogno 2013) 
2.1.2 Elongation/closure – two Ubiquitin-like conjugation systems 
It is often fascinating to observe how nature and evolution conserve specific complex and 
highly functional systems, which are modified and reused in a different context. An example 
of this can be found in autophagy manifested by the two Ubiquitin-like conjugation systems 
ATG12 and LC3. The resemblance to the Ubiquitin-Proteasome-System (UPS), which is used 
for the targeted degradation of short-lived proteins, is striking. 
These two systems work in unison to achieve the lipidation of Microtubule-associated protein 
1A/1B-light chain 3 (LC3), so it can be incorporated in the growing autophagosomal membrane 
(Figure 4). It has been suggested that LC3-lipidation is driving the expansion of the 
autophagosomal membrane. Different autophagy receptor and adaptor proteins, such as p62, 
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optineurin or NBR1 can bind to LC3 via an LIR-motif (LC3-interacting-region) and deliver 
cargo to the autophagosome. How does this lipidation occur? ATG7 (an E1-like Enzyme) and 
ATG10 (an E2-like Enzyme) covalently bind ATG5 to ATG12. ATG5–ATG12 forms 
subsequently a tetramer with ATG16L1, which is an E3-like Enzyme essential for the last step 
of the LC3 conjugation (Eisenberg-Lerner et al. 2009). 
2.1.3 Maturation and degradation  
After the formation of the autophagosome, multiple fusion events with endosomes and 
lysosomes lead to the maturation of the autophagosome, then called autolysosome. The fusion 
is mediated via soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE) complexes (Itakura et al. 2012). The cargo and the inner membrane of the 
autolysosome will be degraded utilizing the hydrolytic enzymes of the lysosome (Mizushima 
& Komatsu 2011). The resulting free fatty acids, sugars, amino acids and 
nucleosides/nucleotides can be used to fuel the cell metabolism and sustain macro molecule de 
novo synthesis (Rabinowitz & White 2010).  
Autophagy plays a vital role in cellular homeostasis. It is not surprising that the impact of 
autophagy on cancer is manifold and double-edged as in other autophagy-related diseases: 
Autophagy can act as a potent tumor suppressor, but also as a tumor benefactor, sustaining 
tumor progression (Figure 2). Therefore, it is crucial to especially assess the role of autophagy 
in the disease outcome at the stage of cancer progression. The next session will describe in 
detail, how autophagy can either suppress tumor development or contribute to tumor 
progression. 
2.2 MODULATION OF AUTOPHAGY 
2.2.1 Nutrient starvation and mTOR 
A key regulator of the transcription of genes involved in autophagy is the nutrient sensor mTOR 
complex 1 (mTORC1). The consensus knowledge is that upon accumulation of amino acids 
(AA) in the lysosomal lumen, v-ATPase interaction with RagB/D transmits an activating signal 
recruiting mTOR to the lysosomal surface where it gets activated by Rheb (Zoncu et al. 2011). 
Leucine was reported to be the most potent activator of mTOR, independent of cell type, but 
other AAs are still required (Meijer et al. 2015). Apart from the previously described 
substrates, such as ULK1/2, does the serine/threonine protein kinase mTOR phosphorylate 
transcription factors, such as basic helix-loop-helix leucine zipper transcription factor EB 
(TFEB) and FoxO under nutrient-rich conditions leading to their retention in the cytoplasm and 
thereby inactivation (Lapierre et al. 2015). Upon a direct mTOR inhibition by small molecules 
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or in response to starvation, these transcription factors localize to the nucleus and can activate 
gene transcription; TFEB genes’ activity leads to the activation of autophagy and lysosomal 
biogenesis (Settembre et al. 2011). 
2.2.2 Inhibition of autophagy 
2.2.2.1 Late inhibitors 
It is of importance to distinguish between two types of inhibition of autophagy. The autophagic 
flux can be blocked by late stage inhibitors. This is done by interfering with lysosomal function 
or by blocking the fusion of the autophagosome with the lysosome. Acid-protease inhibitors, 
such as Pepstatin A and E64d inhibit multiple cathepsins and effectively suppress lysosomal 
function (Jung et al. 2015). V-ATPase inhibitors such as BafA1 and concanamycin interfere 
with the proton pump and block the acidification of the lysosome (Huss & Wieczorek 2009). 
Lysosomotropic agents, such as chloroquine (CQ) or hydroxychloroquine (HCQ) or its 
derivatives, like Lys-05 also prevent the acidification of the lysosome. These agents freely 
diffuse through the plasma membrane of the lysosome, get protonated by the H+ and get 
trapped, which leads to an increase in pH and a lysosomal dysfunction (Pasquier 2015). All 
these drugs lead to an accumulation of autophagosomes and dysfunctional lysosomes, a state, 
which has been shown to confer cell cytotoxicity (Button et al. 2017).  
2.2.2.2 Early inhibitors  
Early autophagy inhibitors target proteins involved in the early stage of the autophagy process. 
The Pan-PI3K inhibitor 3-Methyladenine was the first discovered compound, which inhibits 
VPS34, a Class III PI3K, and therefore the initiation and maturation step of autophagy. Since 
it is a pan-PI3K inhibitor also affecting PI3K class I, which has the opposite to VPS34 effect 
on autophagy, it would simultaneously induce autophagy, leading to some unclear effects (Y.-
T. Wu et al. 2010). This limits the usefulness of the pan-PI3K inhibitors regarding inhibition 
of autophagy. Other noteworthy pan-PI3K inhibitors are Wortmannin and LY294002 widely 
used in research. More specific inhibitors of VPS34 have been developed to overcome these 
issues. Catalytic inhibitors of VPS34 were developed by Sanofi and Novartis; while Sanofi 
discovered a pyrimidinone, with the name SAR405, selective for VPS34, Novartis found a 
bisaminopyrimidine, named PIK-III, also with a high selectivity profile against VPS34 
(Pasquier 2015). I describe in this thesis the activity of SB02024, a new VPS34 inhibitor 
developed by Sprint Bioscience. SB02024 is a potent compound that selectively targets VPS34, 
has good pharmacodynamics properties and significantly reduces the growth of human tumor 
xenograft in mouse models (Paper III). 
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ULK1/2 has been shown to be another potential target to enable an early pharmacological 
autophagy inhibition. It has been shown that ULK2 can substitute ULK1 functions in certain 
cell types (Lee & Tournier 2011), which increase the necessity for a dual ULK1/2 inhibitor. 
MRT67307 is a compound discovered by the Ganley group, which seem to have these 
properties, also including a high potency (Petherick et al. 2015).  
3 ROLE OF AUTOPHAGY IN CANCER 
Cancer is a complex disease, where an accumulation of mutations or epigenetic changes 
underlie cancer development and progression. Oncogenes, which drive proliferation; 
dysfunctional tumor-suppressors, which fail to constrain the transformation of the cell; the 
immune system, which fails to recognize the abnormality: these are many factors necessary 
for the tumor progression. In recent years, a growing understanding of the profound changes 
in cancer cell metabolism led to a new perspective: to view cancer as a metabolic disease. On 
all these levels autophagy has an impact summarized in Table 2. It is undisputed that this 
impact can have positive and negative consequences for the pathogenesis of cancer. It lies in 
the hand of researchers to understand the interplay between autophagy and cancer and find 
the right target in the right context to exploit this knowledge for therapeutic purposes. The 
next section will focus on the dual role of autophagy in cancer. 
3.1 AUTOPHAGY AS A TUMOR SUPPRESSOR MECHANISM 
Extensive in vivo experiments utilizing genetic inhibition of autophagy core genes in various 
tissues demonstrated the role of autophagy as a tumor suppressor in cancer initiation as the 
knock-outs of many of the genes involved in regulation of autophagy lead to tumorigenesis in 
a variety of tumor models (Table 1). 
3.1.1 Genomic stability  
There are several ways of how autophagy contributes to the genomic stability. For example, 
Mitophagy can remove dysfunctional mitochondria, which is a source of ROS, thus reducing 
genotoxicity (Takahashi et al. 2013). Whenever chromosomes or fragments of chromosomes 
are not correctly incorporated in the daughter nuclei, small bodies of the nucleus are formed 
called micronuclei. Autophagy is a standard way for cells to dispose of micronuclei, thereby 
contributing to genomic stability (Rello-Varona et al. 2012). Retrotransposons, genetic 
elements, which can incorporate themselves in the genome using a “copy and paste” 
mechanism, are potentially disrupting genetic stability. This integration occurs with the help of 
an RNA intermediate, which is susceptible to autophagic degradation; hence autophagy 
contributes to genomic stability (Guo et al. 2014).  
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Table 1: Murine models with various knock-outs of key components of the autophagy signaling and their 
phenotype. 
Gene target Phenotype Ref 
AMBRA1 Spontaneous tumorgenesis Cianfanelli et al, 2015 
ATG4c Fibrosarcoma Marino et al, 2007 
ATG5  
(mosaic) 
Benign hepatic 
neoplasms Takamura et al, 2011 
ATG5/7  
(lung specific) 
KRASG12D 
lungcarcinoma Strohecker et al, 2013 
ATG5/7  
(lung specific) 
BRAFV600E 
lungcarcinoma Rao et al, 2014 
ATG5/7  
(pancreas specific) 
KRASG12D pre-
malignant  
pancreatic lesions 
Rosenfeldt et al, 2013;  
Yang et al, 2014 
ATG7  
(liver specific) 
Benign hepatic 
neoplasms Takamura et al, 2011 
ATG7 (hematopoietic 
stem cells) 
Neoplastic bone 
marrow Mortensen et al, 2011 
BECN1+/- 
Lymphoma,  
lung & liver 
carcinoma,  
Wnt1-driven 
carciogenesis 
Liang et al, 1999; Qu et al 2003; Yue et al, 
2003; Mortensen et al, 2011,(22) 
3.1.2 Oncogenes / Tumor-suppressors  
Multiple reports imply that autophagy receptor p62 has an oncogenic function. It is usually 
degraded via the autophagic pathway; its ectopic overexpression (or its presence due to 
autophagy impairment) can stabilize oncoproteins such as Twist1 (Qiang et al. 2014) or act as 
a signal transducer for NF-!B signaling (Duran et al. 2008). p62 has also been shown to be 
responsible for metabolic changes in hepatocellular carcinoma. In a recent study it was shown 
that phosphorylated p62 could activate the transcription factor Nrf2, which directs glucose to 
the glucuronate pathway and glutamine towards glutathione synthesis; both increasing 
chemotherapeutic resistance and proliferative capacity of the cancer cell (Saito et al. 2016). 
Thus, keeping p62 levels low via active autophagy may contribute to tumor suppression.  
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Activation of an oncogene is connected to tremendous stress for the cell. This strain is usually 
countered by oncogene-induced cell death (OID) or oncogene-induced senescence (OIS) in 
normal cells. It has been shown that deletion, knockdown or inhibition by small molecules of 
several components of the autophagy core machinery (mainly targeting Beclin-1, ATG5 or 
ATG7) can limit both OID and OIS (Young et al. 2009), again suggesting a function of 
autophagy in tumor suppression.  
A report investigating the correlation between low Beclin-1 expression in WNT1-driven breast 
cancer and aggressiveness implied a function for Beclin-1 in a non-autophagic role in 
mammary development (Cicchini et al. 2014).  
Reports that autophagy is taking part in the degradation of the mutant, but not the wild-type 
TP53 suggests another tumor suppressive function of autophagy. Mutant TP53 can exert a 
dominant-negative effect by blocking the function of the remaining wild-type TP53 allele in 
heterozygous cells. It was shown that ectopic expression of Beclin-1 or ATG5 lead to a 
reduction of mutant TP53 levels, while knock-down of these autophagy genes via RNA-
interference (RNAi) lead to accumulation of mutant TP53 (Choudhury et al. 2013).  
3.1.3 Immune response  
One first line of defense of the innate immune system are macrophages residing in tissues and 
continuously scanning their environment; as soon as signals are received, they would trigger 
an immune response. Tissue damage, for instance, can lead to the release of danger-associated 
molecular patterns which would activate such an acute inflammatory response; pathogens, 
invading the tissue, can be recognized by the macrophages due to pathogen-associated 
molecular patterns. The macrophages get also activated to dispose of dead cells and initiate 
tissue repair and regeneration. This activity is accompanied by mitochondrial stress, due to 
ROS production and proinflammatory cytokine release. Overactivation of macrophages can 
lead to prolonged inflammation and thereby can contribute to oncogenesis. Autophagy is one 
way to counteract this process, by degrading mitochondria and thereby reducing ROS 
production.  
Immune evasion by the tumors is one the hallmarks of cancer; it is necessary for the malignant 
tumors to stay undetected by the antigen-presenting-cells (APCs), which otherwise would 
promote their destruction via innate and adaptive immune systems. It has been shown that 
autophagy-mediated release of ATP can recruit and activate APCs, thus increasing tumor 
antigen recognition by these cells. Indeed, a decreased autophagy through a decreased ATP 
secretion could prevent tumor cell detection by the immune system (Wang et al. 2013).  
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3.2 AUTOPHAGY AS TUMOR BENEFACTOR  
Although autophagy plays a suppressive role in early tumorigenesis (see above) it turned out 
to be necessary for established tumors to survive various cellular stresses such as lack of 
nutrients, hypoxia, low pH and Endoplasmatic Reticulum (ER) stress (Figure 5). The 
prerequisite for metastasis and invasion, two features of tumor progression, is the loss of cancer 
cell adhesion, providing the ability to migrate manifested by epithelial-mesenchymal transition 
(EMT). Autophagy that was shown to be able to prevent anoikis (Kenific & Debnath 2015), 
can thus contribute to EMT. Indeed, inhibition of autophagy was shown to limit metastasis and 
invasiveness and therefore the progression of cancer to more advanced stages (Galluzzi et al. 
2015). High levels of autophagy in tumors were shown to correlate with a poor disease outcome 
(Lazova et al. 2012) strengthening the role played by autophagy in the maintenance of tumor 
cell survival. Autophagy is also vital for the maintenance of cancer stem cells (CSCs), which 
can exhibit high levels of basal autophagy. It has been shown that the tumor-forming ability of 
mammary CSCs is impaired in vivo when BECN1 or ATG4A is knocked down using RNAi 
(Wolf et al. 2013; Gong et al. 2013). A multitude of factors, which are primarily connected to 
Figure 5: Autophagy in malignant transformation (Galluzzi et al. 2015) 
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the ability of autophagy to counter cellular stress could be accounted for tumor progression 
(Table 2). Metabolic stress, the interaction with the tumor microenvironment and the ability to 
resist therapy-induced cell death are the factors this thesis will pay particular attention to.  
 
3.3 AUTOPHAGY IN ANTI-CANCER THERAPY 
3.3.1 Autophagy in radiotherapy 
Two standard first-line treatments for a multitude of cancer types are chemo- and radiotherapy, 
aside from surgical removal of a tumor. Radiotherapy is strongly associated with autophagy. 
The question whether autophagy may be beneficial for the tumor cells to survive this treatment 
or not has been extensively discussed, as reviewed by Yang et al. Multiple reports have shown 
a positive correlation between upregulation of autophagy and resistance to radiotherapy. 
Contradictory to these reports were observations that autophagy would enhance the anticancer 
effect of radiotherapy and that the inhibition of autophagy would promote cell survival (Yang 
et al. 2015). The take-home message from these studies, each focused on a particular cell line 
or the corresponding tissue, is the importance of the context specificity in order to determine 
the role of autophagy in the treatment outcome. Even more extensive are the literature reports 
about the cytoprotective and cytotoxic role of autophagy under chemotherapeutical treatment, 
which will be discussed in the following chapter.  
3.3.2 Autophagy and Chemotherapeutics 
It is, perhaps, not surprising that many of the chemotherapeutic drugs that induce DNA or 
organelle damage, induce autophagy. Many reports show that autophagy induced by 
chemotherapy may protect tumor cells from cytotoxicity (Nagelkerke et al. 2015). However, 
some reports contradict this notion and instead suggest the importance of autophagy for 
therapy-induced cell death (Gozuacik & Kimchi 2007; Grandér & Panaretakis 2010). David 
Gewirtz tries to tackle this problem by the introduction of a new classification of autophagy in 
anti-cancer treatment, suggesting autophagy induced by chemo- or radiotherapy being either 
cytoprotective, nonprotective, cytostatic or cytotoxic (Gewirtz 2014). This categorization 
imposes a new level of complexity to the inherently difficult task of understanding the 
contribution of autophagy to therapy-resistance. It also implies the necessity to improve 
scientific methods, which are currently represented by the apparent use of genetic or 
pharmacologic inhibition of autophagy in the quest of establishing its relevance.  
  19 
3.4 AUTOPHAGY AND CELL METABOLISM 
3.4.1 Autophagy and metabolic stress 
One of the hallmarks of cancer, so-called “Warburg-effect,” implies a profound switch of 
energy metabolism in the cancer cell from the OXPHOS to the energetically less favorable 
anaerobic glycolysis. This radical reprogramming is driven by oncogenes like RAS, AKT, and 
MYC and causes an enormous amount of cellular stress. When OXPHOS, as well as the 
process of Beta-oxidation of lipids are reduced, the cell in return increases the expression of 
genes involved in glucose uptake and glycolysis, as well as start utilizing other sources of 
energy such as glutamine (Mazurek & Shoshan 2015), as depicted in Figure 6 (The figure refers 
to Ahmai et al, chapter 3 in the book).  
It has been postulated that autophagy in this context serves two purposes. First, it dampens the 
effect of the metabolic reprogramming by providing the cell with amino and fatty acids. 
Secondly, autophagy may provide energy sources from the tumor microenvironment. An 
increased glutaminolysis would lead to an increase in ammonia ions as a result of the enzymatic 
reactions of glutaminase and glutamate dehydrogenase. Ammonia would in turn increase 
autophagy in ULK1 dependent (Li et al. 2016) and independent manner (Cheong et al. 2011) 
. Since it is a volatile compound, it is released into the stroma thereby elevating autophagic flux 
in cancer-associated fibroblasts, CAFs, which in turn decreases their mitochondria numbers 
and thus the OXPHOS potential of these stromal cells. CAFs would have in turn to switch to 
glycolysis to compensate for the energy deficit, which could lead to the secretion of lactate and 
other high-energetic compounds that tumor cells would use as an additional energy source 
(Mazurek & Shoshan 2015). In concert with this model, it was reported that RAS-driven 
tumors show an addiction to autophagy even when external stress stimuli such as nutrient-
deprivation are lacking (Maycotte et al. 2014). 
It is important to mention here another aspect of autophagy in supporting the resistance of 
cancer cells to the stringent metabolic environment. Uncontrolled cell proliferation and 
unbalanced angiogenic signaling in a tumor lead to heterogeneous vascularization and therefore 
a limited blood supply. As a consequence, some tumor regions become continuously low on 
nutrient and oxygen availability leading to starvation and hypoxia, respectively. Both states are 
potent triggers of autophagic flux, which helps tumor cells to withstand this harsh environment. 
Thus, pharmacological inhibition of autophagy could lead to sensitization of human cancer 
cells to hypoxia (Rouschop et al. 2010).  
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3.4.2 Autophagy and tumor acidosis  
Switch to glycolysis for energy production has its consequences. Thus, when glucose is 
metabolized, either aerobically or anaerobically, but the entry of pyruvate to the citric cycle is 
limited, it leads to the production of lactate. Moreover, ATP hydrolysis and decarboxylation 
reactions contribute to produce acid equivalents and protons(Corbet & Feron 2017). Cancer 
cells upregulate membrane transporters to effectively excrete these metabolites to maintain a 
physiological intracellular pH (pHi); this, however, consequently lowers the extracellular pH 
(pHe) in the tumor microenvironment (Gillies et al. 2008). Thus, the metabolic shift to 
glycolysis leads to a decrease in the pH of the tumor microenvironment. The low pHe can lead 
to a reduced leucine uptake, an inhibition of mTOR, and subsequently activation of autophagy 
(Marino et al. 2012). Multiple reports have shown that exposure to an acidic environment is a 
prominent trigger of autophagy induction (S. Wu et al. 2013; Marino et al. 2012; Wojtkowiak 
et al. 2012).  
 
 
Figure 6: Altered cell metabolism in cancer (Mazurek & Shoshan 2015) 
Autophagy, in turn, has an essential function in the adaption of cancer cells to acidosis, since 
inhibition of autophagy increases cytotoxicity in cells exposed to low pH (Wojtkowiak et al. 
2012; Marino et al. 2012; Zhang et al. 2017). The precise mechanism of how autophagy helps 
cells to survive acidic environment is not known. It has been postulated that the involvement 
of autophagy in the maintenance of mitochondrial integrity could be one of the mechanisms 
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behind it (Namba et al. 2014). A second hypothesis is that autophagy helps the cells to 
cannibalize neighboring cells exposed to acidic stress, similarly to the known activity of 
autophagy in digesting some intracellular pathogens (Marino et al. 2012).  
3.4.3 Autophagy and glucocorticoids 
GCs are catabolic steroids that oppose the action of insulin in the body, and regulate energy 
metabolism in a variety of tissues in response to hypoglycemia, anoxia and stresses such as 
tissue damage (Rose & Herzig 2013). Distinct cell types respond differently to GCs: in muscle, 
GCs suppress glucose uptake and glycogen synthesis and cause breakdown of cell protein; in 
the liver, GCs induce gluconeogenesis, lipogenesis and represses fatty acid oxidation. GCs can 
also regulate cell differentiation, for example, in the early development of lung, in T-cell 
differentiation and during bone development. They can also suppress pro-inflammatory 
signaling and inhibit immunological responses (Coutinho & Chapman 2011). GCs are readily 
used in anti-cancer treatment, particularly for the treatment of blood cancers. Notably, as 
described in part 2.3 of this thesis, high doses of GCs are used for the treatment of leukemia. It 
was found in our lab and by others that GCs induce autophagy in leukemic cells (Laane et al. 
2009; Swerdlow et al. 2008), indicating a catabolic state similar to nutrient starvation. Indeed, 
probably not surprisingly, GCs inhibit glucose uptake and metabolism also in ALL cells, and 
this may lead to autophagy induction (Buentke et al. 2011). However, the mechanisms of 
autophagy induction, as well as the role of autophagy in GC-induced apoptosis of ALL cells, 
is not fully understood, and one of the studies in this thesis addresses this question.   
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4 RESULTS & DISCUSSION 
The general aim of this thesis was to investigate the role of autophagy in anti-cancer therapy, 
in particular in chemotherapeutics. The dual nature of autophagy in cancer, as described in the 
Introduction, its tissue-and context-specificity and absence of simple methods of detection in 
vivo obscured its role in anti-cancer treatment and hampered the development of drugs 
targeting autophagy. In the studies of this thesis, we focused on the induction of autophagy by 
anti-cancer drugs and on the alternative ways of autophagy regulation and inhibition using both 
known approaches and novel compounds targeting autophagy.  
4.1 PAPER I  
Tumor acidosis enhances cytotoxic effects and autophagy inhibition by Salinomycin on 
cancer cell lines and cancer stem cells.  
Motivation 
One consequence of the metabolic adaptation to rapid growth of cancerous cells is tumor 
acidosis. Autophagy has been shown to aid tumor cells in surviving the acidic environment 
and, also, to contribute to chemotherapy resistance. Especially a subpopulation of tumor cells, 
designated as cancer stem cells (CSC) have been associated with the ability to metastasize, with 
disease relapse and with enhanced resistance to anti-cancer therapy. These cells were shown to 
depend on autophagy for their survival. The only presently available autophagy inhibitors for 
the clinical use are lysosomal inhibitors. One such inhibitor widely used in clinical trials is 
Hydroxychloroquine (HCQ); however, HCQ was shown to have compromised cell uptake 
properties in acidic environment; thus, the search for new and useful autophagy inhibitors that 
target cells also in acidic conditions is imperative. Another drug that was reported to inhibit 
autophagy is Salinomycin (SAL); however, some contradictory reports were demonstrating 
both the induction as well as inhibition of autophagic flux, as its mechanism of action. This 
cytotoxic compound is an acidic ionophore, and therefore we sought out to investigate the 
cytotoxic effect of SAL treatment on several cancer cell lines in the low pH conditions as 
compared to normal cell culture conditions. SAL has been reported to selectively target breast 
CSC, which prompted us to elucidate its effect on the autophagic flux in cancer cells with an 
emphasis on CSCs.  
Main findings 
We found that SAL is a potent autophagy inhibitor, particularly in acidic conditions, in a 
melanoma, an osteosarcoma, and a colorectal cancer cell line. In the latter cell line, we could 
show that SAL, in contrast to CQ, can penetrate the acidic core of multicellular spheroids 
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efficiently blocking autophagic flux. The compound was also able to decrease cell viability and 
diminish clonogenic survival of these cells.  
Further, we found that SAL efficiently blocks autophagic flux in breast cancer cells as well. 
CSC derived from either breast cancer cell lines, or primary tumor cells showed reduced 
viability and limited ability to form mammospheres under treatment with SAL, in particular, 
when cultured under low pH conditions. Using mass spectrometry, we could confirm that 
intracellular SAL accumulation is pH dependent, which mostly explained its enhanced activity 
under low pH conditions. Thus, SAL is a good candidate for the development of a drug for the 
clinical use that will inhibit autophagy and specifically target CSCs particularly in the acidic 
conditions of the tumor microenvironment.  
Discussion 
Tumor acidosis is an important but frequently overlooked feature, which has to be considered 
in drug development. An acidic environment fostered intracellular accumulation of SAL, and 
therefore this compound is a good candidate for further drug development against cancer. We, 
however, have not addressed the question whether the accumulation of SAL also leads to an 
increase in its activity and therefore it remains to be investigated. Autophagy that contributes 
to the resistance to chemotherapy and tumor progression is a good target for therapy. SAL is 
efficiently inhibiting autophagy as we showed in several cancer cell lines. There have been 
some conflicting reports of SAL’s effect on autophagy: it might not be as contradictory as it 
seems, however, but merely a result of misinterpretation of the experimental results, namely of 
the accumulation of LC3-II, as a marker of autophagy. Unfortunately, no other markers, such 
as the degradation of an autophagic adaptor p62, as a measure for autophagic flux, has been 
used in the studies describing SAL as an inducer of autophagy (Jangamreddy et al. 2013). We 
also found SAL to efficiently inhibit autophagy in CSC, which are notoriously difficult to 
eradicate by treatment. Thus, inhibition of autophagy by SAL may underlie its cytotoxic effect 
on CSCs. Other reports pointed at the SAL-mediated effect on OXPHOS by inner 
mitochondrial membrane hyperpolarization and mitochondrial matrix acidification (Managò 
et al. 2015); this, however, could not entirely explain the sensitivity of CSC to SAL, despite a 
reported dependence of CSCs on OXPHOS (Batlle & Clevers 2017). Another, more plausible 
explanation could be an ability of SAL to sequester iron in lysosomes, catalyzing a Fenton 
reaction. This produces ROS, degrades the lysosomal membrane and leads to ferroptosis (Mai 
et al. 2017). Iron is crucial for CSC maintenance, and iron depletion has been used as a strategy 
to target CSCs in other studies (Ninomiya et al. 2017). In conclusion, our data shed new light 
on the mechanism of action of SAL as a blocker of autophagic flux, its CSC targeting properties 
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under low pH conditions and thus strengthens a prospect for its further developing into 
anticancer therapy. 
4.2 PAPER II 
Metabolic reprogramming of acute lymphoblastic leukaemia cells in response to 
glucocorticoid treatment. 
Motivation  
Glucocorticoids (GC) are a major part of the standard treatment of acute lymphoblastic 
leukemia (Pui et al. 2015). Despite the 50-year history of the use of GCs in the clinics, the 
precise mechanism of this metabolic drug’s action is still unclear. Although it has been shown 
that GCs induced apoptotic cell death is dependent on GC-receptor mediated induction of its 
target genes (Holleman et al. 2009; Hulleman et al. 2009; Jing et al. 2014), it remains unknown 
what metabolic pathways are affected and involved in the sensitivity of ALL cells to GCs. Two 
previous studies in our group pointed at the inhibition of glucose uptake and metabolism and 
the induction of profound autophagy prior to apoptosis by the GC dexamethasone (Dex) in 
ALL cells that undergo apoptosis in response to this drug (Laane et al. 2009). However, not all 
of the responses can be explained by the inhibition of glucose uptake, and the mechanisms of 
the induction of autophagy and its role in the cytotoxic effects of GCs is still unclear. Therefore, 
in this study, we assessed the global response to Dex in kinetics in the GC-sensitive pre-B-ALL 
cell line by integrating metabolomics and high coverage proteomics data to elucidate the 
metabolic changes caused by GC treatment. 
Main findings 
Using integration of metabolomics and proteomics, we could confirm that GC treatment 
induces downregulation of cellular pathways necessary for proliferation, such as pyrimidine, 
purine and polyamine synthesis. Also, the metabolites derived from glycolysis in concert with 
the enzymes of the glycolytic pathway and the TCA cycle metabolites were inhibited. Many of 
these changes could be contributed to a decrease of protein levels of a master regulator of cell 
proliferation and metabolism, c-Myc. We also found a down-regulation of the enzymes in the 
fatty acid synthesis and upregulation of enzymes involved in β-oxidation. We found a robust 
increase of CDP-choline after 24 h treatment with Dex indicating de novo phospholipid 
synthesis. Further, we could detect a decrease in glutamine uptake, whereas glutamine 
synthesis was surging. This regulation was revealed by an increase in overall intracellular 
glutamine and by the increase of glutamate-ammonia-ligase (GLUL) mRNA and protein level, 
an enzyme that converts glutamate to glutamine utilizing ammonia ion. In this study, we also 
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monitored the induction of autophagy and of apoptotic cell death followed GC treatment of 
ALL cells. We found that by accelerating the GLUL-catalyzed reaction by either depleting 
culture medium of glutamine or by adding of a precursor, α-ketoglutarate reduced autophagic 
flux and, to some extent, reduced cell death in ALL cell lines. It was shown before that low 
GLUL expression was one of the three markers predictive of poor disease outcome and the 
relapse in pediatric ALL patients. Analysis of available data sets of GC-treated primary ALL 
cells grown as mouse xenografts (patient-derived xenografts, PDX) revealed that induction of 
GLUL by GC Dex was significant in the GC sensitive PDX and not in the resistant ones (Jing 
et al. 2014). Our data revealed activation of glutamine synthesis by GCs in the cells undergoing 
autophagy and apoptosis and suggested that induction of GLUL by GC treatment may be 
predictive of sensitivity to these drugs. 
Discussion 
This was the first study to our knowledge when the GC-induced changes in leukemic cells were 
investigated in combined metabolomic and proteomic-based approaches. Our data could 
confirm previous reports of GC-induced effects on leukemic cell metabolism, down-regulation 
of c-Myc, inhibition of glycolysis and TCA cycle, and the stall of cell proliferation (Buentke 
et al. 2011; Boag et al. 2006; Rose & Herzig 2013). This evidence validates the quality of our 
dataset. Some of our findings, such as an upregulation of the enzymes involved in OXPHOS 
pathway after prolonged exposure to GC could indicate an attempt of tumor cells to 
dynamically compensate for the loss of energy production through the glycolytic pathway, 
which is a central pathway for energy production in ALL cells (so-called Warburg effect). 
Similarly, induction of enzymes of the β-oxidation pathway may also reflect a metabolic 
reprogramming and a shift from lipid anabolism to catabolism. Also, despite this, we found 
that ALL cells increased synthesis of CDP choline, required for de novo synthesis of most 
phospholipids. This production could be due to the increased demand for intracellular 
membranes because of the membrane blebbing during apoptosis, but also due to an increase in 
autophagy, which is characterized by the formation of vacuoles surrounded by a double 
membrane (Girardi et al. 2011). We have studied in more detail another puzzling observation, 
namely a robust upregulation of glutamine synthesis, an energy-costly process, which is being 
induced despite an abundance of glutamine in the culture medium and the precarious situation 
of imminent cell death. One possible explanation could be the role of this process in ammonia 
regulation; the reaction, which is being catalyzed by GLUL sequesters ammonia, which can be 
toxic to cells (Suárez et al. 2002). It has been shown that ammonia can induce autophagy but 
also can block lysosomal function at higher concentrations. In any case, increase in ammonia 
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levels will be manifested by the accumulation of autophagic vacuoles (Eng et al. 2010). Our 
data indeed point at a possible role of ammonia in the induction of autophagy by GCs in ALL 
cells since fostering the reaction that sequesters ammonia resulted in a decrease of autophagic 
flux and even of cell death. These data allowed us to speculate that the induction of GLUL and 
the glutamine synthesis may reflect the need to sequester cytotoxic ammonia. Significant 
induction of GLUL mRNA by Dex in the sensitive ALL PDX as opposed to the resistant ones 
together with the previously suggested role of GLUL as a predictive marker allows us to 
propose that induction of GLUL and glutamine synthesis are involved in GC-induced cell 
death.  
4.3 PAPER III  
Autophagy inhibition by small molecule inhibitors of Vps34 improves sensitivity of breast 
cancer cells to Sunitinib. 
Motivation 
A variety of anticancer drugs, including cytotoxic chemotherapy and novel targeted agents 
were shown to induce autophagy (Janku et al. 2011). Multiple reports have addressed the role 
of this autophagy induction and shown that it protects from cell death since autophagy 
inhibition could increase sensitivity of different types of cancer cell lines to chemotherapeutics 
(Selvakumaran et al. 2013; Qadir et al. 2008; Pan et al. 2014). These findings led to the 
initiation of a multitude of clinical trials using hydroxychloroquine (HCQ, an FDA approved 
anti-malaria drug) in combination with chemotherapeutics (Onorati et al. 2018). HCQ inhibits 
autophagy at the late stage since it is a lysosomal blocker. These trials have shown, however, 
modest effects. One reason could be a poor cellular uptake of CQ in the acidic tumor 
microenvironment (Pellegrini et al. 2014). In addition, the autophagy-unrelated effects of CQ 
are known, casting doubts on its specificity regarding autophagy inhibition (Piao et al. 2017).  
One aim in this study was to screen a library of all existing anticancer drugs for their potential 
to induce autophagy, and then to identify the drugs, which in combination with autophagy 
inhibition would increase their cytotoxic effects.  
Secondly, we intended to develop a highly potent and specific autophagy inhibitor, to 
investigate the potential of selective inhibition of autophagy as compared to the lysosomal 
inhibition in the combinational anticancer therapy. For this, we took advantage of our screening 
results and used the drugs identified in the screen for the combination studies.  
Main findings 
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We have found that 104 out of 306 anticancer drugs induce autophagy in the screening model 
system based on the GFP-LC3 puncta formation, a method widely used for monitoring 
autophagy. Of these, 16 showed enhanced cytotoxicity when autophagy was genetically 
inhibited using RNAi. We narrowed down the selection of the drugs to 6, which could also 
induce autophagy in a second similar model system, a breast cancer cell line expressing GFP-
LC3. Finally, we have selected two tyrosine kinase inhibitors, Erlotinib and Sunitinib based on 
their performance in the screening and on the promising potential of these drugs in the 
treatment of breast cancer shown in the pre-clinical studies. We describe here the characteristics 
of a novel and potent small molecule inhibitor with selective properties against VPS34, 
SB02024. SB02024 inhibited breast cancer xenografts in vivo and increased the sensitivity of 
breast cancer cell lines to Erlotinib and Sunitinib in vitro.  
Discussion 
Researchers have previously attempted to identify bioactive compounds that induce autophagy, 
such as the screen of the Institute of Chemistry and Cell Biology (ICCB) library of and of the 
National Cancer Institute (NCI) mechanistic set library (S. Shen et al. 2011). In that study, a 
large proportion of the various compounds, including DNA damaging drugs, induced 
autophagy, which demonstrated the proof-of-principle. On the other hand, our screen of the 
FIMM drug library, containing most of anti-cancer drugs, provides data better applicable for 
translational research since these are the drugs actually used in clinical and preclinical practice 
and at physiologically relevant concentrations (Saeed et al. 2017). Further, in order to identify 
drugs whose efficacy was increased by autophagy inhibition, we applied siRNA-mediated 
knock-down of autophagy genes, ATG7 and VPS34. As a result, while 1/3 of the drugs from 
the library were able to induce autophagy, only 16 drugs were found to have increased 
cytotoxicity upon autophagy inhibition could be beneficial for the treatment outcome. We 
believe that the results are underestimated, most likely due to the transient nature of the RNAi 
approach and the dynamic nature of autophagy process. Nevertheless, based on the fact that 
many of the hits in the screening represented targeted therapeutic molecules, we concentrated 
on the two tyrosine kinase inhibitors that may have a promising therapeutic potential in breast 
cancer treatment. Further, we have assessed their cytotoxic effects in breast cancer cell lines in 
combination with pharmacological autophagy inhibition. For this, we used a selective small 
molecule inhibitor of VPS34, SB02024, that was developed by Sprint Bioscience. The activity 
of this novel compound in the xenograft models of breast cancer demonstrated that inhibition 
of VPS34 can be a valid strategy in breast cancer treatment. Also, combining SB02024 with 
Sunitinib increased Sunitinib cytotoxic effects in different in vitro experimental settings. 
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Moreover, SB02024 was able to sensitize MCF-7 and MDA-MB-231 breast cancer cell lines 
to Erlotinib, which these cells were otherwise completely resistant to in our experiments. 
Finally, our novel compound was as potent as the reference VPS34 inhibitor and even more 
potent than the lysosomal inhibitor in its additive effects on cancer cell cytotoxicity. These 
results provide a sound basis for further preclinical and clinical studies of SB02024 and its 
combinations with Sunitinib or Erlotinib in the treatment of breast cancer, and thus strongly 
support VPS34 as a promising target in anti-cancer treatment. 
4.4 PAPER IV 
Regulation of RASAL2 and RASAL2-AS1 during autophagy. 
Motivation 
Autophagy is an essential pathway securing cellular homeostasis, especially under stress 
conditions. The delicate balance between catabolism and anabolism requires tight regulation. 
Recently, long-non-coding RNAs (lncRNA) have emerged next to transcriptional and 
translational regulation in the role of fine-tuning protein expression but also protein function 
(Kopp & Mendell 2018). In this study, we sought out to identify novel lncRNA and proteins, 
which are differentially expressed when autophagy is induced and to study their link to 
autophagy regulation.  
Main findings 
We have found that RASAL2-AS1, a primarily nuclear-located lncRNA, and its sense 
counterpart, mRNA of the protein-coding gene RASAL2, were induced upon autophagy 
activation, via mTOR inhibition either by small molecules or by amino-acid starvation. In 
contrast, RASAL2 protein levels were either marginally increased or even decreased under 
conditions of prolonged autophagy induction. This decrease could be partially rescued by the 
addition of lysosomal inhibitors, which block the late stage of autophagy. Moreover, a 
knockdown of the critical autophagy regulator ATG7 caused a massive accumulation of 
RASAL2 protein. These data reinforced the hypothesis that autophagy may degrade RASAL2. 
We could demonstrate that knock-down of RASAL2-AS1 led to an increase of the RASAL2 
transcript and also of the protein levels suggesting a negative regulation of RASAL2 by 
RASAL2-AS1. Furthermore, we showed that knock-down of RASAL2 inhibited LC3-lipidation 
and puncta formation in the GFP-LC3 transfected cell line. Using the bioinformatical analysis, 
we have identified multiple LC3-interacting regions (LIR) domain in the RASAL2 sequence, 
which could provide a starting point for functional studies to understand the role of RASAL2 
in LC3 lipidation. 
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Discussion 
Autophagy is regulated at different levels and by a large number of proteins organized in 
cascades in a well-orchestrated and structural fashion (Lorin et al. 2013). The lncRNA 
networks can regulate transcription of genes involved in cancer; lncRNA specific expression 
can be associated with therapy resistance, and this knowledge can help to understand the 
mechanistic processes in cells and to develop novel diagnostic and prognostic biomarkers 
(Grandér & Johnsson 2016). AS-RNA represent one class of lncRNA. Notably, up to 70% of 
mammalian protein-coding transcripts have antisense partners pointing at an essential role of 
these transcripts in gene regulation (Huang et al. 2015; Villegas & Zaphiropoulos 2015). 
Identifying differentially expressed AS-RNA can also lead to the identification of novel 
protein-coding genes involved in the crucial processes for cancer cells. 
The function of RASAL2, on the other hand, is well-known: it is a RAS-GTPase activating 
protein, GAP, shown to inhibit a family of oncogenic RAS proteins, involved in cancer 
development and progression (J. Shen et al. 2013). The role of RASAL2 in autophagy has, to 
our knowledge, never been addressed. RASAL2 can interact with each of the four members of 
RAS subfamily, MRAS, KRAS, HRAS and NRAS (Szklarczyk et al. 2014), and as a RAS-
GAP, it can be involved in the inhibition of their function. Activated RAS is known to induce 
signal pathways leading to cell growth, survival and differentiation and could lead to inhibition 
of autophagy via the PI3K-mTOR axis. However, RNAi mediated knockdown of RASAL2 did 
not result in any noticeable changes of phosphorylated ERK, a downstream target of the RAS 
pathway, in one experiment that we have performed. Furthermore, mTOR was inhibited in our 
experiments either by KU-0063794 or through AA-starvation. Thus, we hypothesized that the 
involvement of RASAL2 in the autophagy induction is likely to be independent of its role in 
regulating RAS protein activity. On the other hand, the regulation of RASAL2 by the RASAL2-
AS1 may have an impact on the RAS signaling, and this remains to be investigated. 
The gradual upregulation of RASAL2-AS1 and RASAL2 RNA over time, when either KU or 
AA-starvation are activating autophagy, may indicate that their transcription is induced in the 
second phase response. In response to starvation, transcriptional induction of multiple 
autophagy genes like LC3B, GABARAPL1, ATG12, VPS34, Beclin-1 or ULK2 mediated by 
e.g., the transcription factor forkhead box transcription factor class O 3 (FoxO3), has been 
reported (He & Klionsky 2009). In our experiments, RASAL2 and RASAL2-AS1 were both 
upregulated by either mTOR inhibitors or by AA-starvation. Moreover, a pharmacological 
activator of mTOR inhibited expression of both transcripts further supporting their regulation 
by the transcription factors controlled by mTOR. There is, however, another aspect of 
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regulation of mTOR activity namely through its recruitment to the lysosome surface by the Rag 
small GTPase complex allowing the small GTPase Ras homolog enriched in brain (RHEB) to 
ultimately activate mTOR (J. Kim & E. Kim 2016). Previous reports describe the necessity of 
ATP hydrolysis by the vacuolar H(+)-adenosine triphosphatase ATPase (V-ATPase) for amino 
acids to promote such a mTORC1 translocation to the lysosomal membrane (Zoncu et al. 
2011). In our experiments, however, blocking V-ATPase by BafA1 did not result in any 
changes of RASAL2-AS1 and RASAL2 transcription under either basal conditions or upon 
autophagy induction suggesting that localization of mTOR to the lysosomes may not be 
involved. This data suggested that RASAL2 protein might be degraded through an autophagic 
process. This observation was confirmed by strikingly elevated RASAL2 protein levels when 
we inhibited autophagy by RNAi with ATG7 and Vps34. Thus, we hypothesized that RASAL2 
is induced by mTOR inhibition and is rapidly degraded by autophagy, suggesting the existence 
of a negative feedback mechanism between RASAL2 and autophagy.  
RASAL2 mRNA expression can also be regulated by the lncRNA RASAL2-AS1, as we could 
show that a knockdown of RASAL2-AS1 leads to increased RASAL2 mRNA levels, under either 
basal conditions or upon autophagy induction. The mechanism of the AS-RNA-mediated 
RASAL2 mRNA expression was not addressed in this study. The RASAL2-AS1 and RASAL2 
variant 2 lie nearby head to head and therefore do not show any overlap (Kent et al. 2002; 
Villegas & Zaphiropoulos 2015). Also, the subcellular localization of RASAL2-AS1 to the 
nucleus may suggest that the mechanism of its action may be through epigenetic modifications, 
such as recruitment of repressors/epigenetic modifiers to the RASAL2 promoter.  
Interestingly, however, we did not observe any noticeable effect of the RASAL2-AS1 
knockdown on autophagy, in contrast to the RASAL2 knockdown. The RASAL2-AS1 
knockdown, however, alleviated the autophagy-dependent RASAL2 degradation in AA-
starved cells providing evidence that regulation by RASAL2-AS1 can have apparent phenotypic 
effects on RASAL2 protein. The AS-RNA can provide a fine-tuned regulation of expression 
of genes, as we showed before (Johnsson et al. 2013), which might be hard to reveal 
considering a dynamic RASAL2 protein turn-over during autophagy induction. Thus, further 
studies are needed to confirm and elaborate on the role of AS-RNA-mediated RASAL2 
regulation in autophagy as well as the mechanistic role of RASAL2 in the autophagic process.  
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In memoriam Dan Grandér 
 
 
 
When I was applying for my dissertation (like always stretching deadlines, ein bißchen)  
I thought I would have considered everything: The application, this bureaucratic monstrosity, 
spanning short of 160 pages was neatly printed out. The papers were present  
(including ethical permits, retina scan of my left eye and elementary school report)  
and I had a solid six hours to go.  
I felt  
the silver lining of relief dawning at the horizon.  
But, as so often, things were a bit more complicated and I ended up biking over 25 km 
through a stormy night, negating complications.  
 
This night ride will always stay in my mind. It led me through numerous neighborhoods of 
Stockholm and it was a little like a journey through time.  
I thought about the pleasure I got from meeting so many people here...  
Creative kinds, ambitious types, one smarter than the other!  
And after a windy road I found myself close to where I first set foot coming from Uppsala 
5 years ago, at Karlberg Station in front of Dannes apartment, full of melancholy and I wish, 
oh I wish so badly, he would come down the stairs, smile to me and say ‘Slowly, but surely’ 
one more time.  
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First of all, Katja… my Doktormutter. I cannot thank you enough for your limitless support 
and encouragement. You have a heart of gold and a soul of a philosopher, combining 
seamlessly and effortlessly scientific rationale and empathy. Your humbleness is only being 
shadowed by your sharp mind, a combination every professor should have! Спасибо 
Angelo, my brilliant co-supervisor, full of energy, thank you for your tremendous support; 
you are the incarnation of pubmed! It never fails to amaze me how your mind works; if an 
experiment fails your immediately see alternatives; instead of walls you see opportunities.  
My moist friends:  
Linda, the academic path and your own group is a given, I wish I would have only one tenth 
of your intellect and your humor. Thanks for keeping me up2date in Icelandic matters.  
Elin, thanks for all the fun. I will miss your OCD and all the Nerf gun fights (and all the 
regular fights for that matter; it was always fun to discuss STUFF. See you in industry! 
/dʒ/ aaaaaazmin,. You have such a great sunny side and esprit. Thanks for fantastic 
midsummers and just being such an amazing person. I would say ‘Never change’, but I know 
you won’t! #RacistThursday. Am seeing you actually already in the industry.  
Nathanael, Mr. Andreeeeeews thanks for all the AWs. You have a fantastic enthusiasm, 
never let anyone take it away! You just fit right in with your dry humor. PI #2. 
Sander, miss you buddy. Thanks for a good time.  
My colleagues: 
Maaaaaaaartin, I really miss saying that. And listening to your computational flow 
dynamics of Gubbes Pasta á la Norma. I would have loved to have seen you together with 
Mikke doing ants experiments in the centrifuge. 
Lotte, Thank you for your help and your kindness. It was a pleasure working with you in the 
group. You had always a smile on your lips!    
Vasilios, I really hope we will manage to go for a run. I admire your clear headedness and 
your passion for even the littlest thing. 
Jason, Yo! 
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Magda, thank you for your patience and for teaching me all there is about screening 
procedure. Roland, thank you for going ‘meta’ in metabolomics; it was lots of fun to discuss 
wild theories! Paola thank you for a good time either in the lab or on forest raves. Florian, 
thank you for having the best Core Facility at KI! Altijd leuk om ff bij te kletsen.  
 
The Sprint connection: 
Áine, Andreas, Jenny, Jessica, Santi, Tiago and everyone at Sprint Bioscience. It is great 
to see how academic industry can be. Thank you giving me a home on last stretch of my 
PhD. The spirit and energy in this company is truly unique.  
 
Conference Call: 
Many thanks to the Nov2k organization team: Ahmed, Annika, Bettina, Elin, Kristina, 
Malte, Veronika and of course Karolina. It was one of the highlights of my time at KI.  
And ofc to the various From Basics to Clinics orga teams; esp. to Sebastian, Burcu, 
Carolin, Gonçalo, Helena, Sandra and Tina! You guys rock! What a team effort! 
 
Lords of Sci-Fi aka George’s Brewery:  
George, thanks for lots of psychology & philosophy bouldering sessions. You are an 
awesome dude; I can’t stress this enough! Wolfgäng, the incredible result of crossing 
German Engineering with Australian Relaxation. It was a pleasure traveling Europe with 
you! David G., du Kraftpacket, with a pinch of OCD… your unique serene view on the 
world is amazing. Stay as you are! Michael, Danish DIY PI and 3-dan of puns; missing your 
‘Fuck-it, let’s do it’ attitude. David S. Jetzt MACH doch EINFACH Digga! +++  
 
CCK:  
Alessandro, Bruce, Elin, Emarn, Matilda, My, Pedro, Sophia: You made this department 
easily a second home for me. Thanks for lots of fikas, pubs and seminars! 
 
Andreas, Bertrand, Daniel, Jonas, Lars and Mimi: Thanks for your engagement in the 
department and lots of interesting chats! 
 
Erika & Sören: Thank you for making my life so much easier! 
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The Ukrainian connection: 
Greg, the only person I have first met in bed before being on the feet, my favorite ultra-
running dentist and over all superman; Dmitry, the most passionate and still easy-going 
surgeon I know and Mirjam, never too shy to jump into the balkan beats crowd: Thanks for 
all the great dinners and concerts. I wish I would have been more there! 
 
Susi, thank you for being my climbing partner; it was always fun die Mauer zu bezwingen. 
And thanks for all the CMM pubs! Shout out to Eliane J Super gezellig.  
 
Thank you, Tiago, for organizing soo much, Simona for being the first at the dance floor and 
again Gonçalo for being the voice of reason from time to time, when needed.  
 
The Maaslos crew: It is fantastic to have you as friends… Every year we get a bit older, but 
everything stays the same with you; Auf Pfingsten! Isi!!!! My soulmate mit Bindungsangst. 
Ewiger Runningpartner, der Würme zum glühen bringt. Rockstar Lausi, die einfach mal 
macht! Und das mit einem Lachen auf den Lippen. Caro mit ihren unglaublichen Charme und 
Stil, ob PI oder Farmer… oder Pharma? J Stella natürlich Pharma! Aber auch Vollzeit 
Bäcker, wie auch immer das zeittechnisch geht….miraTOR, Bob, Leo und Marcimarc…. 
VIELEN DANK euch allen!  
 
Last but not least, thank you Sofia for always being there, in my best, but also my worst 
times, sharing passion for art, music and diving and ‘just’ being part of my life.  
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